← Back to blog
ValueJuly 27, 2026

Buy the Dip Monday: When the Earnings Yield Hits 17% and Analysts See 778% Upside

Top 5 Pixie Picks

Only Pro and Free Trial readers get meta-analysis of the top 5 ranked Value stocks.

Sign in

6. QUALCOMM Incorporated (QCOM)

P/E: 17.97 | Earnings yield: 5.6% | 52w drawdown: -35.7%

ROIC of 39.5% and 55.4% gross margin reflect pricing power in mobile chipsets, while the 7.3% FCF yield and 2.2% dividend yield add shareholder return visibility. Revenue grew 13.7% year over year, and the 35.7% drawdown from peak has compressed the valuation to a 18 P/E against a normalized 10-year P/E of 30.1.

Insider filings show activity from Tricoire, McLaughlin, and CFO Palkhiwala in mid-July, though the 4.8% short interest and modest 6% analyst upside to $177.10 suggest the market is waiting for confirmation that the AI device cycle translates to sustained chip demand. News flow ties QUALCOMM to the broader Big Tech earnings test this week, with results due July 29.

The debt-to-equity ratio of 0.72 and EV/EBITDA of 19x leave less valuation cushion than peers in the semiconductor space, and if the mobile replacement cycle softens or if China's domestic chip push accelerates, the thesis weakens.

7. VanEck Gold Miners ETF (GDX)

P/E: 17.02 | Earnings yield: 5.9% | 52w drawdown: -35.8%

The 17 P/E and 36% drawdown from peak position the ETF as a leveraged play on gold's next move, with the miners historically outperforming physical gold in rally phases. The normalized 10-year earnings yield of 1.2% reflects the sector's cyclical volatility, but the current 5.9% earnings yield suggests the market is pricing in a reversion to mean gold prices.

News highlights the 0.40% fee drag as a headwind for physical gold ETFs, and the mining ETF adds operational leverage that amplifies downside if spot gold retraces. With no FCF yield or dividend yield data in the pipeline, the ETF lacks the income buffer that individual miners like Newmont provide.

8. GSK plc (GSK)

P/E: 13.40 | Earnings yield: 7.5% | 52w drawdown: -16.8%

The 72.4% gross margin and 19.9% ROIC reflect GSK's position in specialty pharma, while the 4.6% FCF yield and 3.5% dividend yield add income support. Revenue grew 4.1% year over year, and the 17% drawdown from peak leaves the analyst target implying 12.9% upside to $57.94.

Insider activity from Squarer, Oliger, and Bogle on July 15 aligns with news of Jideytro winning FDA approval, a catalyst that expands the HIV franchise and adds near-term revenue visibility. Earnings on July 28 will clarify full-year guidance and any margin expansion tied to the new launch.

The debt-to-equity ratio of 1.17 and EV/EBITDA of 18.7x leave less valuation cushion than U.S. pharma peers, and if the FDA approval does not translate to market share gains in a crowded HIV landscape, the thesis narrows.


What to Watch

July 28: KLA and GSK earnings will clarify whether the semiconductor equipment cycle holds and if GSK's Jideytro approval translates to near-term revenue beats.

July 29: QUALCOMM reports as part of the Big Tech earnings wave; guidance on AI device chip demand and the mobile replacement cycle will drive the next leg.

July 30: First Solar earnings arrive with tariff litigation and operations risk in focus; margin trajectory and full-year capacity guidance will reset the valuation debate.

August 6: Versant Media reports; the question is whether sports rights deals and insider buying signal a turnaround or if the 5.3% revenue decline extends into the second half.


Go Deeper

The value screener identifies companies trading at steep discounts to normalized earnings, high free cash flow yields, and strong balance sheets.

Check out the full screener →

Pro-only analytics

Named tickers from this article open in the app with Pro or an active trial.

Sign in

Stock Pixie Pro

See the full Buy the Dip screen — every pick, every metric, every day.

The app shows up to 10 rows on Free; the top 5 by Pixie rank keep ticker, name, and recent close private. Posts may name the top 5 for context. Pro and trial show every row on the screener, full identifiers, and the rest of Pro.

Start your free trial

Or start with the free Market Brief Digest

Where the market stands before the open, in plain language, every trading day. No account needed.

About the Stock Pixie Score

The Stock Pixie Score is a 0–10 composite that measures how well a stock matches the criteria for that screen. Scores reflect the strength of quantitative signals across valuation, quality, and trend factors weighted for the specific screener. A higher score means stronger alignment; above 8 indicates the algorithm finds the setup compelling across most of the metrics it tracks. It is a filter, not a forecast.

The Fine Print

Stock Pixie is not a registered investment adviser and does not offer financial advice. It is a stock screening platform that scores and ranks stocks using quantitative signals. You are responsible for your own research and investment decisions. Past performance does not guarantee future results.